Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: A new potential therapy for the treatment of melanoma

Experimental Cell Research

Volumn 316, Issue 12, 2010, Pages 1994-2007

  Karasic, Thomas B ^a   Hei, Tom K ^a   Ivanov, Vladimir N ^a  

^a Columbia University ^*  (United States)

Author keywords

AKT; Apoptosis; IGF 1R; Melanoma; TRAIL

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PICROPODOPHYLLIN; PROTEIN KINASE B; PROTEIN NRAS; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROBLAST; GENE INACTIVATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 77953479620     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.04.014     Document Type: Article

References (55)

1. Satyamoorthy K., Li G., Gerrero M.R., Brose M.S., Volpe P., Weber B.L., Van Belle P., Elder D.E., Herlyn M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 2003, 63:756-759.
2. Perlis C., Herlyn M. Recent advances in melanoma biology. Oncologist 2004, 9:182-187.
3. Reed J.C. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat. Clin. Pract. Oncol. 2006, 3:388-398.
4. Schaefer U., Voloshanenko O., Willen D., Walczak H. TRAIL: a multifunctional cytokine. Front. Biosci. 2007, 12:3813-3824.
5. Ashkenazi A., Herbst R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Investig. 2008, 118:1979-1990.
6. Greco F.A., Bonomi P., Crawford J., Kelly K., Oh Y., Halpern W., Lo L., Gallant G., Klein J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008, 61:82-90.
7. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008, 27:6207-6215.
8. Ivanov V.N., Partridge M.A., Johnson G.E., Huang S.X., Zhou H., Hei T.K. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp. Cell Res. 2008, 314:1163-1176.
9. Ivanov V.N., Bhoumik A., Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003, 22:3152-3161.
10. Ivanov V.N., Zhou H., Partridge M.A., Hei T.K. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. Cancer Res. 2009, 69:3510-3519.
11. Hersey P., Zhang X.D. Treatment combinations targeting apoptosis to improve immunotherapy of melanoma. Cancer Immunol. Immunother. 2009, 58:1749-1759.
12. Ivanov V.N., Hei T.K. Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J. Biol. Chem. 2004, 279:22747-22758.
13. Meier F., Busch S., Lasithiotakis K., Kulms D., Garbe C., Maczey E., Herlyn M., Schittek B. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br. J. Dermatol. 2007, 156:1204-1213.
14. Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Pract. Res. Clin. Endocrinol. Metab. 2008, 22:625-638.
15. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 2008, 8:915-928.
16. Larsson O., Girnita A., Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br. J. Cancer 2005, 92:2097-2101.
17. Satyamoorthy K., Li G., Vaidya B., Patel D., Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res. 2001, 61:7318-7324.
18. Girnita A., All-Ericsson C., Economou M.A., Astrom K., Axelson M., Seregard S., Larsson O., Girnita L. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin. Cancer Res. 2006, 12:1383-1391.
19. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
20. van 't Veer L.J., Burgering B.M., Versteeg R., Boot A.J., Ruiter D.J., Osanto S., Schrier P.I., Bos J.L. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell. Biol. 1989, 9:3114-3116.
21. Smalley K.S., Xiao M., Villanueva J., Nguyen T.K., Flaherty K.T., Letrero R., Van Belle P., Elder D.E., Wang Y., Nathanson K.L., Herlyn M. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 2009, 28:85-94.
22. Wu H., Goel V., Haluska F.G. PTEN signaling pathways in melanoma. Oncogene 2003, 22:3113-3122.
23. Tsao H., Goel V., Wu H., Yang G., Haluska F.G. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 2004, 122:337-341.
24. Resnicoff M., Coppola D., Sell C., Rubin R., Ferrone S., Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 1994, 54:4848-4850.
25. Yuen J.S., Akkaya E., Wang Y., Takiguchi M., Peak S., Sullivan M., Protheroe A.S., Macaulay V.M. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Mol. Cancer Ther. 2009, 8:1448-1459.
26. Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O., Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 2004, 64:236-242.
27. Maloney E.K., McLaughlin J.L., Dagdigian N.E., Garrett L.M., Connors K.M., Zhou X.M., Blattler W.A., Chittenden T., Singh R. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 2003, 63:5073-5083.
28. Yee D. Targeting insulin-like growth factor pathways. Br. J. Cancer 2006, 94:465-468.
29. Riedemann J., Macaulay V.M. IGF1R signalling and its inhibition. Endocrinol. Relat. Cancer 2006, 13:S33-S43. Suppl 1.
30. B. Sehat, A. Tofigh, Y. Lin, E. Trocme, U. Liljedahl, J. Lagergren, O. Larsson, SUMOylation Mediates the Nuclear Translocation and Signaling of the IGF-1 Receptor, Sci Signal 3 ra10.
31. Hilmi C., Larribere L., Giuliano S., Bille K., Ortonne J.P., Ballotti R., Bertolotto C. IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J. Investig. Dermatol. 2008, 128:1499-1505.
32. Krasilnikov M., Ivanov V.N., Dong J., Ronai Z. ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 2003, 22:4092-4101.
33. Haass N.K., Sproesser K., Nguyen T.K., Contractor R., Medina C.A., Nathanson K.L., Herlyn M., Smalley K.S. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin. Cancer Res. 2008, 14:230-239.
34. Smalley K.S., Lioni M., Dalla Palma M., Xiao M., Desai B., Egyhazi S., Hansson J., Wu H., King A.J., Van Belle P., Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol. Cancer Ther. 2008, 7:2876-2883.
35. Stahl J.M., Sharma A., Cheung M., Zimmerman M., Cheng J.Q., Bosenberg M.W., Kester M., Sandirasegarane L., Robertson G.P. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004, 64:7002-7010.
36. Satyamoorthy K., DeJesus E., Linnenbach A.J., Kraj B., Kornreich D.L., Rendle S., Elder D.E., Herlyn M. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res. 1997, 7(Suppl 2):S35-S42.
37. P. Lopez-Bergami, H. Kim, A. Dewing, J. Goydos, S. Aaronson, Z. Ronai, c-Jun regulates phosphoinositide-dependent kinase 1 transcription: implication for Akt and protein kinase C activities and melanoma tumorigenesis, J. Biol. Chem. 285 (2010) 903-913.
38. Vasilcanu R., Vasilcanu D., Rosengren L., Natalishvili N., Sehat B., Yin S., Girnita A., Axelson M., Girnita L., Larsson O. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene 2008, 27:1629-1638.
39. Chin L., Garraway L.A., Fisher D.E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006, 20:2149-2182.
40. van Elsas A., Zerp S.F., van der Flier S., Kruse K.M., Aarnoudse C., Hayward N.K., Ruiter D.J., Schrier P.I. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am. J. Pathol. 1996, 149:883-893.
41. Tuveson D.A., Weber B.L., Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 2003, 4:95-98.
42. R. Beroukhim, C.H. Mermel, D. Porter, G. Wei, S. Raychaudhuri, J. Donovan, J. Barretina, J.S. Boehm, J. Dobson, M. Urashima, K.T. Mc Henry, R.M. Pinchback, A.H. Ligon, Y.J. Cho, L. Haery, H. Greulich, M. Reich, W. Winckler, M.S. Lawrence, B.A. Weir, K.E. Tanaka, D.Y. Chiang, A.J. Bass, A. Loo, C. Hoffman, J. Prensner, T. Liefeld, Q. Gao, D. Yecies, S. Signoretti, E. Maher, F.J. Kaye, H. Sasaki, J.E. Tepper, J.A. Fletcher, J. Tabernero, J. Baselga, M.S. Tsao, F. Demichelis, M.A. Rubin, P.A. Janne, M.J. Daly, C. Nucera, R.L. Levine, B.L. Ebert, S. Gabriel, A.K. Rustgi, C.R. Antonescu, M. Ladanyi, A. Letai, L.A. Garraway, M. Loda, D.G. Beer, L.D. True, A. Okamoto, S.L. Pomeroy, S. Singer, T.R. Golub, E.S. Lander, G. Getz, W.R. Sellers, M. Meyerson, The landscape of somatic copy-number alteration across human cancers, Nature 463 (2010) 899-905.
43. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
44. Gritsko T., Williams A., Turkson J., Kaneko S., Bowman T., Huang M., Nam S., Eweis I., Diaz N., Sullivan D., Yoder S., Enkemann S., Eschrich S., Lee J.H., Beam C.A., Cheng J., Minton S., Muro-Cacho C.A., Jove R. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 2006, 12:11-19.
45. G. Hatzivassiliou, K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, R. Alvarado, M.J. Ludlam, D. Stokoe, S.L. Gloor, G. Vigers, T. Morales, I. Aliagas, B. Liu, S. Sideris, K.P. Hoeflich, B.S. Jaiswal, S. Seshagiri, H. Koeppen, M. Belvin, L.S. Friedman, S. Malek, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature.
46. Ivanov V.N., Hei T.K. Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression. Exp. Cell Res. 2006, 312:4120-4138.
47. Chawla-Sarkar M., Leaman D.W., Jacobs B.S., Borden E.C. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J. Immunol. 2002, 169:847-855.
48. Shiraishi T., Yoshida T., Nakata S., Horinaka M., Wakada M., Mizutani Y., Miki T., Sakai T. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res. 2005, 65:6364-6370.
49. Menu E., Jernberg-Wiklund H., Stromberg T., De Raeve H., Girnita L., Larsson O., Axelson M., Asosingh K., Nilsson K., Van Camp B., Vanderkerken K. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 2006, 107:655-660.
50. Catrina S.B., Lewitt M., Massambu C., Dricu A., Grunler J., Axelson M., Biberfeld P., Brismar K. Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival. Br. J. Cancer 2005, 92:1467-1474.
51. Sachdev D., Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther. 2007, 6:1-12.
52. Stromberg T., Ekman S., Girnita L., Dimberg L.Y., Larsson O., Axelson M., Lennartsson J., Hellman U., Carlson K., Osterborg A., Vanderkerken K., Nilsson K., Jernberg-Wiklund H. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 2006, 107:669-678.
53. Ashkenazi A., Holland P., Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 2008, 26:3621-3630.
54. Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem. Sci. 2006, 31:402-410.
55. Smith G.C. F. d'Adda di Fagagna, N.D. Lakin, S.P. Jackson, Cleavage and inactivation of ATM during apoptosis. Mol. Cell. Biol. 1999, 19:6076-6084.